- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07718204
The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients (MedMemos)
17 de julho de 2026 atualizado por: Ahna Pai, Nationwide Children's Hospital
MedMemos: An Intervention to Promote Medication Adherence in Pediatric Allogenic Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to test the MedMemos Intervention with parents and children who have received a bone marrow transplant. The main study questions are:
- Is the MedMemos intervention acceptable to patients and families?
- Is the MedMemos intervention feasible for patients, families, and healthcare providers?
- Does MedMemos help patients and families take their medications better?
Participants will be asked to complete surveys, attend 4 intervention sessions, and use an electronic box or pill bottle to store their medications in.
Visão geral do estudo
Status
Recrutamento
Condições
Intervenção / Tratamento
Descrição detalhada
This study will assess the acceptability, feasibility, and proof-of-concept for MedMemos, a novel medication adherence promotion intervention developed for caregivers of children who received a pediatric hematopoietic stem cell transplant (PAHCT).
Tipo de estudo
Intervencional
Inscrição (Estimado)
25
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Ahna LH Pai, PhD
- Número de telefone: (614) 938-1601
- E-mail: Ahna.Pai@nationwidechildrens.org
Estude backup de contato
- Nome: Sarah N Drake, MS
- Número de telefone: (614) 259-7462
- E-mail: sarah.drake2@nationwidechildrens.org
Locais de estudo
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43205
- Recrutamento
- Nationwide Children's Hospital
-
Contato:
- Ahna LH Pai, PhD
- Número de telefone: (614) 938-1601
- E-mail: Ahna.Pai@nationwidechildrens.org
-
Contato:
- Sarah N Drake, MS
- Número de telefone: (614) 259-7462
- E-mail: sarah.drake2@nationwidechildrens.org
-
Investigador principal:
- Ahna LH Pai, PhD
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Child had a Pediatric Allogeneic Hematopoietic Cell Transplant (PAHCT)
- Child is 0-12 years of age
- At the time of recruitment child is still in the hospital for PAHCT
- Child's primary caregiver is responsible for administering medical care and is willing to give consent to participate
- Child is prescribed an oral medication regimen at discharge
Exclusion Criteria:
- Caregiver does not speak English, Spanish, or Arabic
- Caregiver is not available to provide written permission for the child's participation
- EMR or medical team report of the caregiver's cognitive status precludes completion of questionnaires
- The child's medical status or condition precludes completion of the study questionnaires as determined by the physician or caregiver
- Caregiver is unwilling to store medication in an electronic monitor
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: MedMemos
This arm will provide participants with the MedMemos Intervention
|
MedMemos is a 4-session tailored adherence promotion intervention that will provide caregivers with a combination of tailored and standardized medication and adherence education videos and a "Medication Management Kit" that provides tailored strategies to target identified barriers to successful medication management.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Intervention Acceptability
Prazo: At the end of session 4 (An average of 14 days following the patient's hospital discharge, up to 28 days following discharge)
|
Intervention acceptability will be demonstrated by caregivers rating MedMemos a mean of ≥ 4 as measured on Acceptability of Intervention Measure, Feasibility of Intervention Measure, and Intervention Appropriateness Measure.
Each measure asks participants to rate statements on a scale of "Completely Disagree" to "Completely Agree" Higher scores indicate greater acceptability, feasibility, and appropriateness.
|
At the end of session 4 (An average of 14 days following the patient's hospital discharge, up to 28 days following discharge)
|
|
Intervention Feasibility - Percentage of patients who enroll out of those approached
Prazo: Enrollment rate will be continually monitored throughout enrollment and final enrollment percentage will be calculated at the close of enrollment. Enrollment is estimated to end during Month 9 of Year 2.
|
Feasibility will be assessed by calculating enrollment rate (total number of patients enrolled / total number of patients approached).
Feasible enrollment will be achieved by enrolling 80% or more of eligible caregivers.
|
Enrollment rate will be continually monitored throughout enrollment and final enrollment percentage will be calculated at the close of enrollment. Enrollment is estimated to end during Month 9 of Year 2.
|
|
Intervention Feasibility - Percentage of intervention sessions and follow-ups completed by enrolled participants.
Prazo: Completion rates will be calculated during the study in real time as part of study monitoring. Final study completion rates will be reported after the final follow-up is complete. Follow-ups are estimated to be complete Month 11 of Year 2.
|
Feasibility will be assessed by calculating the percentage of MedMemos sessions attended and the number of follow-up visits completed.
Feasibility will be achieved if 80% or more of MedMemos sessions are attended by participants and if 80% or more of follow-up visits are completed by participants.
|
Completion rates will be calculated during the study in real time as part of study monitoring. Final study completion rates will be reported after the final follow-up is complete. Follow-ups are estimated to be complete Month 11 of Year 2.
|
|
Intervention Feasibility - Percentage of the intervention protocol delivered by the interventionist.
Prazo: Intervention fidelity will be monitored in real time to maintain adherence to the intervention protocol. Final intervention fidelity will be reported after the final MedMemos session is completed. Sessions are anticipated to end in Month 11 Year 2.
|
Feasibility of the intervention delivery will be assessed by calculating the intervention fidelity.
Fidelity will be assessed by a member of the lab not involved in intervention delivery using a fidelity checklist developed by the study Principal Investigator.
Feasibility of the intervention delivery will be achieved if fidelity checklist scores are 80% are greater (80% or more of the intervention delivered across the study)
|
Intervention fidelity will be monitored in real time to maintain adherence to the intervention protocol. Final intervention fidelity will be reported after the final MedMemos session is completed. Sessions are anticipated to end in Month 11 Year 2.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adherence to immunosuppressant medication as assessed by electronic monitor
Prazo: Daily adherence will be monitored for each patient after discharge through the 3-month follow-up.
|
To establish proof-of-concept adherence to immunosuppressants will be monitored for all patients.
Proof-of-concept will be established if ≥75% children take ≥75% of their immunosuppressant medication doses at all follow-up time points as measured by electronic monitor.
|
Daily adherence will be monitored for each patient after discharge through the 3-month follow-up.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de maio de 2026
Conclusão Primária (Estimado)
31 de dezembro de 2028
Conclusão do estudo (Estimado)
31 de dezembro de 2028
Datas de inscrição no estudo
Enviado pela primeira vez
9 de abril de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
17 de julho de 2026
Primeira postagem (Real)
21 de julho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
21 de julho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
17 de julho de 2026
Última verificação
1 de julho de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- STUDY00004461
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Descrição do plano IPD
This is a rare treatment that treats even rarer diseases.
Although identifiers will be removed from the final dataset, it will still include variables such as diagnosis treated by PAHCT, cell source for transplant (e.g., bone marrow, cord blood), date of transplant, and age at transplant that are frequently important to include in analyses.
Given the rarity of this treatment, the investigators believe there remains the possibility of deductive disclosure of participants with uncommon characteristics (e.g., rare cancer diagnosis).
To protect the rights and privacy of human subjects the investigators will not be sharing IPD, but instead will share de-identified aggregated qualitative data via the Cancer Data Service (CDS) database.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .